A Link between Lung Injury and Inflammatory Myopathies: Making the Diagnosis
Florence Morriello*, Gaetano Caramori, Michael Chin and Mark Bonta
Department of Medicine, University of Toronto, Toronto, Canada

Abstract
Pulmonary fibrosis associated with various connective tissue diseases often presents insidiously but can progress to rapid deterioration. Previous studies have shown that, in the patients with connective tissue diseases, the presence of pulmonary fibrosis has prognostic implications and therefore early detection may be essential in the management of these patients. Our case outlines the close association between pulmonary fibrosis and idiopathic polymyositis. We report the findings of a patient who presented with slow onset progressive exercise dyspnea followed by proximal muscle weakness and joint and skin changes.

Keywords: Muscle inflammation; Interstitial lung disease; Treatment options; Skin changes

Case Report
A 68-year-old Caucasian man presented to the emergency room with a 6-week history of progressive dyspnea associated with dry cough and diffuse pleuritic chest pain. He also complained of muscle weakness and diffuse myalgias which predated his respiratory symptoms, which now impacting on his daily activities. He denied hemoptysis and constitutional symptoms. His General Practitioner (GP) had treated him for a respiratory tract infection with clarithromycin, inhaled albuterol, budesonide and formoterol daily without improvement. A computed tomography (CT) scan of the chest arranged by his GP showed extensive lung fibrosis with honeycombing. He was awaiting a respiratory referral when he developed worsening dyspnea and bilateral leg swelling, at which point he presented to Toronto General Hospital. His past medical history consisted of hypercholesterolemia controlled on rosuvastatin and benign prostatic hypertrophy. He was a lifetime nonsmoker and a nonalcohol user. Currently retired but had worked in the printing business for 40 years.

Blood Work

| WBC   | 16.2 × 10^9/L |
|-------|---------------|
| Neutrophils | 13 × 10^9/L |
| Lymphocytes | 1.56 × 10^9/L |
| Monocytes | 1.04 × 10^9/L |
| Eosinophils | 0.53 × 10^9/L |
| Basophils | 0.03 × 10^9/L |

Hemoglobin 127 g/L
Platelets 314 × 10^9/L
Creatinine 72 mmol/L

**Blood Work**

Electrolytes:

| Sodium | 130 mmol/L |
|-------|------------|
| Potassium | 4.1 mmol/L |
| Chloride | 99 mmol/L |
| Calcium | 2.14 mmol/L |
| Magnesium | 0.85 mmol/L |
| Phosphate | 1.06 mmol/L |

A repeat contrast CT scan of the chest showed (Figure 2) moderate and severe opacity in the right middle lobe and lower lobe respectively, with some traction bronchiectasis. Mild subpleural reticulatation in the left upper lung, moderately severe opacity in the lingula and left lower lobe. Normal airway anatomy was observed on fiberoptic bronchoscopy. Bronchoalveolar lavage (BAL) fluid examination ruled out infection. The BAL differential cell count revealed: 39% neutrophils, 1% lymphocytes and 60% bronchial lining cells. Pulmonary function testing (Table 2) was consistent with severe restrictive lung disease. A structurally normal heart, ejection fraction >55% and estimated

*Corresponding author: Florence Morriello, Department of Medicine, University of Toronto, Toronto, Canada, Tel: +1 416-978-2011; E-mail: Florence.morriello@utoronto.ca

Received January 03, 2016; Accepted February 18, 2016; Published February 22, 2016

Citation: Morriello F, Caramori G, Chin M, Bonta M (2016) A Link between Lung Injury and Inflammatory Myopathies: Making the Diagnosis. J Clin Case Rep 6: 720. doi:10.4172/2165-7920.1000720

Copyright: © 2016 Morriello F, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
systolic pulmonary artery pressure of 27 mmHg on transthoracic echocardiogram. Magnetic resonance imaging (MRI) of the lower extremities (Figure 3) showed scattered bilateral edema, suggestive of inflammatory changes as seen in inflammatory myopathy. No muscle atrophy was observed. Muscle biopsy of gluteus minimus showed large variation in fiber size with many atrophic fibers of the skeletal muscles, extensive fiber splitting with increased internal nuclei, foci of lymphocytic inflammation, moderate fibrosis and fatty infiltration. Frozen sections showed no inclusions or 'ragged red' fibers. These findings were more consistent with polymyositis. Malignancy workup was all negative. HIV risk factor screening was negative.

Discussion

Polymyositis with interstitial lung disease (ILD)

Polymyositis (PM) is a multi-systemic connective tissue disorder which typically affects skeletal muscles but can also affect the lungs. Its prevalence ranges from 0.5 to 8 cases per million with the prevalence of lung involvement ranging from 5% to as high as 64% in some studies [1]. Early diagnosis of ILD in PM has prognostic implications and therefore it is essential to screen for ILD in these patients. The exact nature of the autoimmune destruction of skeletal muscle and lung parenchyma is not entirely clear but experimental studies have shown it is likely a targeted cell mediated immunity in response to an exogenous antigen or autoantigen [2].

The clinical picture of polymyositis with ILD

The typical clinical presentation of PM is that of proximal muscle weakness with progressive worsening over weeks to months. Patients present with symptoms such as difficulty climbing stairs, combing their hair and getting up from a sitting position. Interstitial lung disease can present either acutely which can be rapidly progressive, subacutely or as a subclinical disease with no respiratory symptoms [3]. Commonly it presents with an insidious onset of dyspnea and non-productive cough. ILD has been reported to occur before myositis in 20% of cases and if diagnosed at the same time or after the diagnosis of myositis, the duration between the two diagnoses is typically less than 12 months [3]. In this case, our patient's initial symptoms were respiratory and within weeks he developed proximal muscle weakness. His first CT scan of the chest showed a pattern of severe lung fibrosis indicating ILD. He met four of the required criteria for a definitive diagnosis of ILD, these included: (1) symmetric proximal muscle weakness; (2) elevated CK; (3) EMG showing myopathic changes and (4) muscle biopsy showing features of myositis. Therefore it is essential to screen for ILD in these patients. The exact nature of the autoimmune destruction of skeletal muscle and lung parenchyma is not entirely clear but experimental studies have shown it is likely a targeted cell mediated immunity in response to an exogenous antigen or autoantigen [2].

Diagnosis of polymyositis

Idiopathic polymyositis and dermatomyositis are subgroups of a heterogeneous group of inflammatory muscle diseases. Table 3 provides a differential diagnosis. The main diagnostic criteria of idiopathic PM requires symmetric proximal muscle weakness, generally subacute onset, elevated serum muscle enzymes (creatine kinase is the most sensitive muscle enzyme and always increases in active disease states to as much as 50 times in some cases1), and inflammatory infiltrates on muscle biopsy [4-6]. Typical cutaneous eruptions are seen dermatomyositis (DM) but not in PM (the only feature distinguishing DM from PM). Electromyography (EMG) showing myopathic changes and muscle biopsy is essential for showing characteristic findings namely multifocal lymphocytic infiltrates surrounding and invading healthy muscle fibers. Our patient met four of the required criteria for a definitive diagnosis of PM, these included: (1) symmetric proximal muscle weakness; (2) elevated CK; (3) EMG showing myopathic changes and (4) muscle biopsy showing features of inflammatory changes as seen in polymyositis or dermatomyositis. There was no muscle atrophy or fatty infiltration observed.

Table 1: Patient's blood work.

| Parameter                          | Value       |
|------------------------------------|-------------|
| Aspartate Aminotransferase (AST)   | 38 U/L (8-20 U/L) |
| Alanine Aminotransferase (ALT)     | 36 U/L (8-20 U/L) |
| Alkaline Phosphatase               | 57 U/L (35-100 U/L) |
| Lactate Dehydrogenase (LDH)       | 336 U/L (100-250 U/L) |
| Erythrocyte Sedimentation Rate     | 70 mm/hr |
| Creatine Phosphokinase (CPK)      | 351 U/L (52-336 U/L) |
| Bilirubin                          | 12 (< 26μmol/L) |
| Anti-nuclear Antibodies (ANA)      | 1:64 |
| Anti-Sjogren's Syndrome-related Antigen A (SSA also termed anti-Ro) | Negative |

Table 2: Pulmonary function testing.

| Test                                | Absolute value | Compared to Predicted Value |
|-------------------------------------|----------------|-----------------------------|
| Pre-bronchodilator forced expiratory volume (FEV1) | 1.2 litres | 37% |
| Pre-bronchodilator forced vital capacity (FVC) | 1.7 litres | 39% |
| FEV1/FVC ratio                      | 93%           |                             |
| Total Lung Capacity (TLC)           | 3.1 litres    | 46%                         |
| Diffusing capacity of the lung for carbon monoxide (DLCO) | 52% |

Table 3: Differential diagnosis of polymyositis with ILD.

| Diagnosis                      | Criteria                                                                 |
|--------------------------------|--------------------------------------------------------------------------|
| Polymyositis                   | Symmetric proximal muscle weakness, elevated serum muscle enzymes, EMG showing myopathic changes and muscle biopsy |
| Dermatomyositis                | Symmetric proximal muscle weakness, elevated serum muscle enzymes, EMG showing myopathic changes and muscle biopsy |
| Dermatomyositis with ILD       | Symmetric proximal muscle weakness, elevated serum muscle enzymes, EMG showing myopathic changes and muscle biopsy, ILD |
| Polymyositis with ILD          | Symmetric proximal muscle weakness, elevated serum muscle enzymes, EMG showing myopathic changes and muscle biopsy, ILD |
| Polymyositis without ILD       | Symmetric proximal muscle weakness, elevated serum muscle enzymes, EMG showing myopathic changes and muscle biopsy |

Figure 2: CT chest with Contrast. Demonstrates in the right lung mild apical fibrosis, mild subpleural reticulation in the right upper lobe, moderate opacity in the right middle lobe with some traction bronchiectasis representing interstitial thickening. Severe opacity in the right lower lobe consisting of reticulation, traction bronchiectasis, likely some subpleural honeycombing. The left lung showed mild subpleural reticulation in the left upper lobe, moderately severe opacity in the lingula consisting of reticulation, and severe opacity in the left lower lobe similar to the right lower lobe.

Figure 3: Magnetic resonance imaging (MRI) of the lower extremities demonstrates scattered bilateral areas of edema in the gluteus minimus and lower quadriceps muscles primarily, more evident on the right side which are nonspecific but suggested inflammatory changes as seen in polymyositis or dermatomyositis. There was no muscle atrophy or fatty infiltration observed.

Table 1: Patient's blood work.
muscle biopsy showing more chronic changes suggesting a subacute presentation of our patient's myositis. In the presence of a patient with idiopathic PM, it is essential to investigate for a concomitant ILD. Typical radiological changes include increased interstitial markings (reticular and nodular opacities) more prominently in the lower lung fields and typically non-specific interstitial pneumonia (NSIP), which is the most common pattern (56.3%). A lung biopsy is needed to confirm the histopathological diagnosis of the ILD when the chest imaging is inconclusive and may also help in determining the prognosis but it is associated with morbidity and mortality and for this reason it is usually reserved for few selected patients [5,7-9]. Our patient's radiological findings were consistent with NSIP. A lung biopsy to confirm the diagnosis was not performed.

Management

The main therapeutic objectives are to improve muscle strength and treat extramuscular manifestations (rash, dysphagia, dyspnea, arthralgia, fever). In general, clinical practice has shown that DM responds better to treatment than does PM [6,10]. Despite a lack of high quality randomized controlled trials, the mainstay of treatment for idiopathic inflammatory myositis with and without ILD are systemic glucocorticoids that usually improve respiratory symptoms, improve muscle strength and normalize serum muscle enzymes (despite a decrease in serum CK alone is not a sign of clinical response). In patients with rapidly worsening disease, it is preferable to administer intravenous methylprednisolone before starting treatment with oral glucocorticoids that usually improve respiratory symptoms, improve muscle strength and normalize serum muscle enzymes (despite a decrease in serum CK alone is not a sign of clinical response). In patients who develop progressive ILD, treatment and pulmonary rehabilitation can improve functional daily performance levels especially in those with chronic progressive ILD [10]. Our patient was started on high dose prednisone (1 mg/kg/daily) and mycophenolate mofetil (500 mg twice daily) and gradually increased to a maximum dose of 1 g twice daily. After starting therapy his respiratory status, proximal muscle weakness improved and his rash disappeared. He continued to require oxygen to maintain normal saturations especially when ambulating and was discharged on home oxygen therapy.

Conclusion

PM/DM with ILD has significant prognostic implications and therefore early diagnosis can affect long term outcome. Given the lack of definitive evidence on therapy, the management of these patients remains challenging. More research on the pathophysiology of this entity may provide further insights and thereby better treatment options which will further impact in patient prognosis, quality of life and long term outcomes.

References

1. Dalakas MC, Hohlfeld R (2003) Polymyositis and dermatomyositis. Lancet 362: 971-982.
2. Benveniste O, Chérin P, Maisonneuve T, Merat R, Chosidow O, et al. (2001) Severe perturbations of the blood T cell repertoire in polymyositis, but not dermatomyositis patients. J Immunol 167: 3521-3529.
3. Schnabel A, Hellrich B, Gross WL (2005) Interstitial lung disease in polymyositis and dermatomyositis. Curr Rheumatol Rep 7: 99-105.
4. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292: 344-347.
5. Dalakas MC (2015) Inflammatory muscle diseases. N Engl J Med 372: 1734-1747.

| Myopathies                         | Skin lesions                  | Muscle weakness Onset | Histopathological features in the muscle biopsy | Serum autoantibodies | Other features                                      | Creatine kinase |
|------------------------------------|-------------------------------|-----------------------|-----------------------------------------------|----------------------|-----------------------------------------------------|-----------------|
| Dermatomyositis (DM)               |                                |                       | Subacute/ Acute                               | Inflammatory infiltrates | Anti-Mi2 Anti-SAE | Investigate for malignancy                        | Increased       |
| DM with severe skin symptoms and rapidly progressive ILD |                                |                       |                                               |                      |                                                      |                 |
| Polymyositis                       | "mechanic's hands"            | Subacute              | Inflammatory infiltrates                       | Anti-Jo1 typically in patients who develop ILD | Investigate for ILD and malignancy                | Increased       |
| Inclusion-Body Myositis            | Not reported                   | Subacute              | inclusions or 'ragged red' fibers             |                      | Investigate for malignancy                        | Increased       |
| Overlap Myositis                   | Cutaneous eruption similar to dermatomyositis | Subacute              | Perifascicular, interstitial and perimysial regions | Antisythene           | Investigate for malignancy                        | Increased       |
| Drug-Induced (Statins/ Antiretroviral drugs) | Not reported                   | Usually acute         | Necrotizing associated with statins           | Anti-HMG-CoA dehydrogenase | Increased               |                 |
| Dystrophic Myopathies              | Not reported                   | Chronic/ Subclinical  | Atrophy and fatty infiltration                |                      | Normal                                              |                 |
| Hypothyroidism                     | Not reported                   | Subacute              | Fibre atrophy and muscle loss                 |                      | Increased                                           |                 |
| Paraneoplastic related myositis    | Not reported                   | Subacute/ acute       | ?                                              | Anti-155/140          | Normal                                              |                 |

Table 3: Differential diagnosis.
6. Dalakas MC (2002) Muscle biopsy findings in inflammatory myopathies. Rheum Dis Clin North Am 28: 779-798.

7. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, et al. (2008) Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 63: 53-59.

8. Padley SP, Hansell DM, Flower CD, Jennings P (1991) Comparative accuracy of high resolution computed tomography and chest radiography in the diagnosis of chronic diffuse infiltrative lung disease. Clin Radiol 44: 222-226.

9. Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138: 1464-1474.

10. Gordon PA, Winer JB, Hoogendijk JE, Choy EH (2012) Immunosuppressant and Immunomodulatory Treatment for Dermatomyositis and Polymyositis. Cochrane Database Syst Rev 15: 8.

11. Moghadam-Kia S, Aggarwal R, Oddis CV (2015) Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. Expert Rev Clin Immunol 11: 1265-1275.

12. Stenzel W, Preuße C, Allenbach Y, Pehl D, Junckerstorff R, et al. (2015) Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy. Neurology 84: 1348-1354.